Icon
+91 94997 68112
Login Register

Belviq - (10 mg; Tablet, Oral)

Lorcaserin Hydrochloride EISAI INC
10 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients.
Yes
***** ** *** ***** ** **** **** ** **** ******* ’*** (**/**/****), ’*** (**/**/****), ’*** (**/**/****), ’*** (**/**/****), ’*** (**/**/****), ’*** (**/**/****) , ’*** (**/**/****), ’*** (**/**/****) , ’*** (**/**/****) *** *** ************ *********. ** ****** **** **** ***** ******* ** ***** ****. ******** ****** ** ********** ****** ** ***** ****. **, **** ** *** ******* *** ****** ******* ****** ***** ****. *****, ********** ********* **** *********, ***** *** ***** ** ********** *** *** *****. ********* ** ********* ******** ******, ********* ***** * **** *** ** ******* '***, '***, '***, '***, '***, '***, '***, '*** *** '***. **, ** *** *** ****** ******* ****** **** ****.
Belviq Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15
***** ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
********* **** *** **** *** **** *** ******* **** *** **** *** **** *** **** *** **** *** ******* **** *** ******* ******* ******* *******
***** ****** **** *** **** *** **** *** *** ********* **** *** **** *** **** *** **** *** **** *** *** ********* **** *** *** ********* *** ********* *** ********* *** ********* (***** ******)
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ ** ***** **, **** ******* **** ******* **** **** *** *** ****
********* ** \ ** *** *, **** ******* ********* ******** ******* **** **** *** *** ****
***** ****** ** \ ** -**- *** ********* ********* ******** ** *** **, ****
  1. *** **, **** : ***** ******** ***** *** ***** ***** *** **** ** **** ******* ’*** , ’*** , ’***, ’***, ’***, ’*** , ’***, ’*** , ’***
  2. *** **, **** : ***** *** ***** ***** * **** ******* ***** ** ******** ***** ** ********.
  3. *** **, **** : **** ******** ***** *** ***** ***** *** **** ** ************* **** ** ******* *,***,*** (*** **, ****), *,***,*** (*** **, ****), *,***,*** (*** **, ****), *,***,*** (*** **, ****), *,***,*** (*** **, ****), *,***,*** (*** **, ****), *,***,*** (*** **, ****), *,***,*** (*** *, ****), *** *,***,*** (*** *, ****)
  4. *** **, **** : ********* *** ********* ********. *****://***.**********.***.***/**********_****/*********/****/********************.***
  5. *** *, **** : ***** *** ***** ***** * **** ******* **** ** ******** ***** ** ********.
  6. *** **, **** : ********* ******** ***** *** ***** ***** *** **** ** **** ******* ’***
  7. ***** *,**** : ***** *** ***** ******* **** *****, ***** *** ***** ** ********** *** *** *****.
  8. *** *, **** : ***** *** ***** ***** * **** ******* ********* ** ****** '***
  9. *** *, **** : ***** ****** *** ********* ********. (**** **- ******) *** *** *** *********.
  10. *** **, **** : ***** *** ***** ******* **** *********, ***** *** ***** ** ********** *** *** *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.